If you’ve been impacted by prostate cancer, the term ‘theranostics’ is probably at the top of your news list. The rapidly emerging treatment modality combines therapy and diagnostics to improve our understanding of each man’s cancer, and how it can be effectively treated, heralding a complete transformation of care.
Impressively, Australia has rapidly established itself as a global pioneer in the field, with clinical trials such as the ProPSMA study and TheraP delivering groundbreaking findings that have helped to establish new standards of care locally and globally.
In this webinar, we bring together experts and survivors to talk about theranostics and you – knowing when to go nuclear, and whether it will work.
This webinar will be hosted by Matt Britland, President of the APPA. Matt will be interviewing David Cade, Chief Executive Officer of Telix Asia Pacific; Associate Professor Shahneen Sandhu, Consultant Medical Oncologist and Researcher at Peter MacCallum Cancer Centre; and Will McDonald, advanced prostate cancer survivor and PCFA Ambassador.
- Forums
- ASX - By Stock
- TLX
- Understanding Telix
Understanding Telix, page-181
-
- There are more pages in this discussion • 1,001 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TLX (ASX) to my watchlist
(20min delay)
|
|||||
Last
$19.13 |
Change
-0.340(1.75%) |
Mkt cap ! $6.401B |
Open | High | Low | Value | Volume |
$19.41 | $19.46 | $18.81 | $121.0M | 6.335M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 7316 | $19.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.13 | 6814 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 12500 | 18.990 |
1 | 1000 | 18.950 |
1 | 3 | 18.910 |
4 | 1715 | 18.900 |
1 | 2000 | 18.890 |
Price($) | Vol. | No. |
---|---|---|
19.370 | 1500 | 1 |
19.450 | 50 | 1 |
19.470 | 500 | 1 |
19.480 | 45 | 1 |
19.490 | 53 | 1 |
Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
Featured News
TLX (ASX) Chart |